Kafui Dey

General

BEDROOM TESTS: Dr Gepi-Attee Reveals sexually stimulating videos were used in Viagra clinical trials

Ghanaian urologist Dr Samuel Gepi-Attee has revealed that researchers used sexually stimulating videos as part of clinical trials to assess the effectiveness of sildenafil, the drug later marketed as Viagra.

By Roberta Gayode Modin ·
Dr. Samuel Geri-Attee

Ghanaian urologist Dr Samuel Gepi-Attee has revealed that researchers used sexually stimulating videos as part of clinical trials to assess the effectiveness of sildenafil, the drug later marketed as Viagra.

Speaking in an interview with Kafui Dey, the retired consultant urologist said the trials involved exposing participants to visual stimulation to measure their erectile responses after taking the medication and compare them with responses without the drug.

Dr Gepi-Attee explained that researchers also took blood samples to establish whether participants had the required levels of the drug in their bodies.

“It involves taking blood samples and things to be sure that the right levels of the drug were being obtained in the patient,” he said.

He said the team subsequently conducted different stimulation tests to assess the medication’s effect on erectile function.

“And then doing various stimulant tests, some of them visually expressive tests, to see what difference it made when you did the test after taking the tablets and when you did the test without taking the tablets,” he explained.

Asked about the nature of the visual tests, Dr Gepi-Attee confirmed that they involved sexually stimulating videos.

He said the researchers sought to obtain objective results by comparing participants’ responses under different conditions.

“You are now doing the testing to be able to report objectively,” he said.

The tests also examined whether some participants experienced erections without visual stimulation.

Dr Gepi-Attee said participants were recruited from a clinic waiting list of people seeking treatment options for erectile dysfunction.

“Generally, what you did was you held a waiting list of people who wanted to come to the clinic for you to give them whatever treatment options you had,” he said.

“So we recruited people from that list to be able to arrange them to test them systematically,” he added.

The urologist also recounted how the research came to focus on erectile dysfunction after sildenafil, which was initially being investigated as a cardiac vessel dilator for conditions such as angina, was found to have an unexpected effect on erectile function.

“Whilst it was being explored for this, some of the candidates for whom the trial was going on started discussing with others,” he recalled.

According to him, participants began comparing their experiences after taking the drug, leading researchers to recognise its effect on erections.

“So it became clear that it had an effect on erectile function,” he said.

Dr Gepi-Attee said the discovery prompted the trial organiser to redirect the research towards erectile dysfunction.

“Once the organizer of the trial noticed it, he said we should target erectile function,” he revealed.

He said he was pleased to have been part of the research team that tested the drug during its clinical phase.

“I am glad that I was one of the original researchers that took it through the clinical phase,” he said.

He added: “I think it was unique and ultimately successful.”

Dr Gepi-Attee said his involvement was particularly relevant because he was already working in andrology, the medical speciality concerned with male reproductive and sexual health.

“It was an area that we were not very successful as urologists in treating,” he said.

He described the medication as offering the promise of stimulating natural erections, adding that he valued the opportunity to contribute to its clinical testing.

Share This Story

Share